Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UF-KURE-BCMA in Relapsed or Refractory Multiple Myeloma
NCT07611149Phase 1Not yet recruiting
- Sponsor
- Kure.ai
- Start
- Sep 2026
- Primary completion
- Sep 2028
01
Overview
Phase 1, open-label trial of UF-KURE-BCMA CAR T-cells in multiple myeloma (MM) (3 arms), sponsored by Kure.ai. Primary endpoint: Dose-Limiting Toxicities at 28 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
UF-KURE-BCMA CAR T-cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07611149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07611149.